Perennial Allergic Rhinitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Perennial Allergic Rhinitis - Pipeline Review, H2 2016

Perennial Allergic Rhinitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Perennial Allergic Rhinitis - Pipeline Review, H2 2016
Published Aug 24, 2016
51 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Perennial Allergic Rhinitis - Pipeline Review, H2 2016, provides an overview of the Perennial Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis
- The report reviews pipeline therapeutics for Perennial Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Perennial Allergic Rhinitis therapeutics and enlists all their major and minor projects
- The report assesses Perennial Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Perennial Allergic Rhinitis


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise correct

  
Source:
Document ID
GMDHC8397IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Perennial Allergic Rhinitis Overview61
Therapeutics Development72
  Pipeline Products for Perennial Allergic Rhinitis Overview71
  Pipeline Products for Perennial Allergic Rhinitis Comparative Analysis81
Perennial Allergic Rhinitis Therapeutics under Development by Companies91
Perennial Allergic Rhinitis Therapeutics under Investigation by Universities/Institutes101
Perennial Allergic Rhinitis Pipeline Products Glance112
  Late Stage Products111
  Clinical Stage Products121
Perennial Allergic Rhinitis Products under Development by Companies131
Perennial Allergic Rhinitis Products under Investigation by Universities/Institutes141
Perennial Allergic Rhinitis Companies Involved in Therapeutics Development158
  Faes Farma, S.A.161
  Glenmark Pharmaceuticals Ltd.171
  Hisamitsu Pharmaceutical Co., Inc.181
  Merck &Co., Inc.191
  Pfizer Inc.201
  Shionogi &Co., Ltd.211
  VentiRx Pharmaceuticals, Inc.221
Perennial Allergic Rhinitis Therapeutics Assessment2310
  Assessment by Monotherapy Products231
  Assessment by Combination Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3314
  (levocabastine hydrochloride + mometasone furoate) Drug Profile331
  Allergen for Asthma and Perennial Allergic Rhinitis Drug Profile341
  asapiprant Drug Profile351
  bilastine Drug Profile362
  desloratadine Drug Profile382
  emedastine difumarate Drug Profile401
  GSP-301 Drug Profile411
  PF-06444752 Drug Profile422
  PF-06444753 Drug Profile442
  VTX-1463 Drug Profile461
Perennial Allergic Rhinitis Dormant Projects471
Perennial Allergic Rhinitis Discontinued Products481
Perennial Allergic Rhinitis Product Development Milestones491
  Featured News &Press Releases491
    Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province491
Appendix502
  Methodology501
  Coverage501
  Secondary Research501
  Primary Research501
  Expert Panel Validation501
  Contact Us501
  Disclaimer511

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Perennial Allergic Rhinitis - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. May 15, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Perennial-Allergic-Rhinitis-Pipeline-Review-H2-2016-2088-16438>
  
APA:
Global Markets Direct - Market Research. (2016). Perennial Allergic Rhinitis - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Perennial-Allergic-Rhinitis-Pipeline-Review-H2-2016-2088-16438>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.